New article dedicated to the Q-PHASE was published in Scientific Reports by Springer Nature. Name of the article is "Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin". 
Recently, a new article dedicated to the study of doxorubicin encapsulated in antigen-targeted apoferritin-based nanovehicle (APODOX-anti-PSMA), and its efficiency and safety in anti-tumor treatment was published in Scientific Reports from Nature Publishing Group (Dostalova, et al, 2018). For analysis and quantitation of nanovehicle internalization into prostate cancer cells, the quantitative phase imaging in combination with the fluorescence detection was performed by Tescan multimodal holographic microscope Q-PHASE. Different degrees of cellular uptake and morphological changes were observed in cells treated with targeted compound, as compared to free DOX or non-targeted APODOX (Fig. 1).

Fig. 1: Quantification of cellular uptake of DOX encapsulated nanovehicle APODOX-anti-PSMA in prostate cancer cells LNCaP. DOX fluorescence micrographs (top panel) were obtained from continuous quantitative phase imaging of cells treated with DOX/APODOX/APODOX-anti-PSMA (bottom panel). Adapted and modified from Dostalova, et al, 2018.  

Video: Time lapse video of APODOX-anti-PSMA uptake in prostate cancer cells LNCaP